Prospective Electronic Polygenic Risk Study - Second Phase

Inclusion Criteria: * 45 ≥ Age \< 65 * ASCVD Risk Score \> 7.5% as defined by the standard pooled cohort equation * Access to and ability to use a smartphone Exclusion Criteria: * Prior diagnosis of coronary disease as defined by prior myocardial infarction (STEMI or NSTEMI), or revascularization (stent or coronary artery bypass grafting) * Prior diagnosis or treatment of glaucoma * Cerebrovascular disease with history of ischemic stroke, TIA, carotid endarterectomy, carotid artery stenting * Peripheral arterial disease with history of claudication, revascularization (stents or bypass) * Current and active high-intensity statin prescription (rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg and atorvastatin 80 mg) * Anti-PCSK9 therapy * Lipid apheresis therapy * Currently enrolled in a clinical trial for lipid lowering therapy * Known statin intolerance to 2 or more statins in the past